NCT01841723View on ClinicalTrials.gov

Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2029

Conditions
Hairy Cell LeukemiaHairy Cell Leukemia VariantRecurrent Hairy Cell LeukemiaRecurrent Hairy Cell Leukemia Variant
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration and biopsy

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow aspiration and biopsy

PROCEDURE

Computed Tomography

Undergo CT

DRUG

Ibrutinib

Given PO

PROCEDURE

Ultrasound Imaging

Undergo ultrasound

Trial Locations (5)

20892

National Institutes of Health Clinical Center, Bethesda

43210

Ohio State University Comprehensive Cancer Center, Columbus

48201

Wayne State University/Karmanos Cancer Institute, Detroit

55905

Mayo Clinic in Rochester, Rochester

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH